Indications
Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
Composition
- Active substance
- somapacitan
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Sogroya
- Active substance
- somapacitan
- ATC code
- H01AC07
- Therapeutic area
- Growth
- Marketing authorisation holder
- Novo Nordisk A/S
- Status
- Authorised